Novel Metabolic Drugs and Blood Pressure: Implications for the Treatment of Obese Hypertensive Patients?
- First Online:
- 502 Downloads
Hypertension and obesity often coexist, exposing patients to cardiovascular and metabolic risks, particularly type 2 diabetes mellitus. Moreover, obesity may render hypertensive patients treatment resistant. We review how drugs recently approved for obesity or type 2 diabetes mellitus treatment affect blood pressure. The weight-reducing drug lorcaserin induces modest reductions in body weight while slightly improving blood pressure. The fixed low-dose topiramate/phentermine combinations elicit larger reductions in body weight and blood pressure. Concomitant improvements in glucose metabolism, adiposity, and blood pressure differentiate the first clinically available SGLT2 inhibitor dapagliflozin from other oral antidiabetic drugs. Yet, the mechanisms through which metabolic drugs affect blood pressure and their interaction with antihypertensive drugs are poorly understood. Blood pressure-lowering effects of metabolic drugs could be exploited in the clinical management of obese hypertensive patients with and without type 2 diabetes mellitus, particularly in patients with difficult to control arterial hypertension.
KeywordsHypertension Obesity Type 2 diabetes Blood pressure Lorcaserin Phentermine/topiramate combination Sodium-glucose co-transporter-2 (SGLT2) inhibition
Recently published papers of particular interest have been highlighted as: • Of importance •• Of major importance
- 13.• Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124:1046–58. Important report on this clinically challenging entity of hypertension that has only recently received broader attention.PubMedCrossRefGoogle Scholar
- 15.•• Jordan J, Yumuk V, Schlaich M, et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens. 2012;30:1047–55. Together with reference 16, this paper summarizes all important epidemiological, pathophysiological and treatment information on obesity-associated hypertension.PubMedCrossRefGoogle Scholar
- 16.•• Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of the Obesity Society and the American Society of Hypertension. J Clin Hypertens (Greenwich). 2013;15:14–33. Together with reference 15, this paper summarizes all important epidemiological, pathophysiological, and treatment information on obesity-associated hypertension.CrossRefGoogle Scholar
- 19.Jordan J, Scholze J, Matiba B, et al. Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes Relat Metab Disord. 2005;29:509–16.Google Scholar
- 34.• Martin CK, Redman LM, Zhang J, et al. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab. 2011;96:837–45. Well-designed study on the weight loss mechanisms of lorcaserin.PubMedCrossRefGoogle Scholar
- 35.Refusal of the Market authorization for Qsiva (phentermine/topiramate). Available at http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002350/WC500139215 pdf 2013.
- 39.•• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–52. Important trial on efficacy data of phentermine/topiramate.PubMedCrossRefGoogle Scholar
- 42.The role of cardiovascular assessment in the pre- and post-approval settings for drugs developed for the treatment of obesity. Available at http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm297240 pdf 2013.
- 47.Nauck MA, Del PS, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015–22.PubMedCrossRefGoogle Scholar
- 48.• Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–31. Well-designed study on the weight loss mechanisms of dapagliflozin.PubMedCrossRefGoogle Scholar